Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

Trial Profile

A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs INCAGN-2385 (Primary)
  • Indications Diffuse large B cell lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Incyte Biosciences International
  • Most Recent Events

    • 17 Sep 2018 According to an Agenus media release, the company received a cash milestone of $5 million from Incyte for the initiation of phase I clinical trial.
    • 27 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 29 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top